Breaking News
April 26, 2019 - Can Obesity Shrink Your Brain?
April 26, 2019 - This oral appliance could help you (and your partner) sleep better
April 26, 2019 - Myelination deficits cause abnormal hypersocial behavior associated with Williams syndrome
April 26, 2019 - New sepsis detector uses photonics to make accurate diagnosis in less than thirty minutes
April 26, 2019 - New study describes process to diagnose rare genetic diseases in record time
April 26, 2019 - Scientists and patients gather in Vancouver to discuss about Stevens-Johnson syndrome
April 26, 2019 - Advance in breakthrough cancer treatment eliminates serious side effects
April 26, 2019 - Discovery about cold sensing could pave way for new pain relief drugs
April 26, 2019 - Children often turn to sugary drinks instead of water
April 26, 2019 - Genome analysis shows the combined effect of many genes on cognitive traits
April 26, 2019 - Patients Caught In Middle Of Fight Between Health Care Behemoths
April 26, 2019 - Drug overdoses among adolescents and young adults on the rise
April 26, 2019 - Implementing a Paperless QC Micro Laboratory”
April 25, 2019 - Obesity linked to a reduction in gray matter
April 25, 2019 - Smart assistants could help combat opioid crisis
April 25, 2019 - Diagnostic stewardship strategy reduces inappropriate testing
April 25, 2019 - Three-antibiotic cocktail eradicates ‘persister’ Lyme bacteria in mouse model
April 25, 2019 - Study investigates how early blindness shapes sound processing
April 25, 2019 - Outcomes Worse for Cancer Patients Seen at Noncancer EDs
April 25, 2019 - Link found between temperament of high-risk infants and obesity
April 25, 2019 - Al Letson explores ties between journalists and doctors at Medicine and the Muse symposium
April 25, 2019 - New mobile phone game can detect people at risk of Alzheimer’s
April 25, 2019 - Scientists discover trigger region for absence epileptic seizures
April 25, 2019 - Stretchy wearable patch can do a health check while you work out
April 25, 2019 - Exercise activates brain circuits associated with memory in older adults
April 25, 2019 - Veggies, Fruits and Grains Keep Your Heart Pumping
April 25, 2019 - Healthy meal kits can boost children’s long-term health
April 25, 2019 - Designing an inexpensive surgical headlight: A Q&A with a Stanford surgeon
April 25, 2019 - States Weigh Banning A Widely Used Pesticide Even Though EPA Won’t
April 25, 2019 - Integrator complex proteins are crucial for healthy brain development in fruit flies, study finds
April 25, 2019 - Device converts brain signals into speech, offering hope for patients
April 25, 2019 - Measles vaccination rates are a ‘public health time bomb’
April 25, 2019 - Maths made easier for scientists students who shun the subject wins award
April 25, 2019 - Researchers decode how cancer drug works in brains of Parkinson’s disease patients
April 25, 2019 - Smarter Brain Cancer Trial Comes to Columbia
April 25, 2019 - Researchers Seek Sage Advice Of Elders On Aging Issues
April 25, 2019 - New chemical synthesis strategy leads to identification of novel, simpler derivatives
April 25, 2019 - Vanderbilt investigators discover link between vascular biology and eye disease
April 25, 2019 - Feces transplantation is effective and provides economic benefits
April 25, 2019 - Eisenhower Health first in Southern California to offer new lung valve treatment for COPD/emphysema
April 25, 2019 - Johns Hopkins researchers uncover role of neurotransmitter in the spread of aggressive cancers
April 25, 2019 - Porvair Sciences offers highly effective P3 microplate for biological sample clean-up
April 25, 2019 - Air pollution increases risk for respiratory hospitalization among childhood cancer survivors
April 25, 2019 - We are sitting more! How bad is that?
April 25, 2019 - Majority of stroke survivors not screened for osteoporosis, despite increased risk
April 25, 2019 - ADHD Screening: MedlinePlus Lab Test Information
April 25, 2019 - Cellular alterations increase vulnerability of obese and diabetic individuals to infection
April 25, 2019 - Association Insurance Pushes On Despite Court Ruling
April 25, 2019 - Traditional and e-cigarette users may be more receptive to smoking cessation interventions
April 25, 2019 - Delving into tumor’s cellular lineage may offer clues for customized therapies
April 25, 2019 - Two studies uncover brain mechanisms underlying decision making process
April 25, 2019 - Cardiometabolic Risk Better ID’d in Children Reclassified to Higher BP
April 25, 2019 - How the obesity epidemic is taking a toll on our bones and joints
April 25, 2019 - E-cigarettes contaminated with dangerous microbial toxins
April 25, 2019 - Researchers document specific characteristics of storefront tobacco advertisements
April 25, 2019 - Oncotype DX-guided treatment could reduce cost for breast cancer care, study suggests
April 25, 2019 - Predicting whether a patient will benefit from chemotherapy
April 25, 2019 - New review highlights how lifestyle affects our genes
April 25, 2019 - Study provides evidence that blood tests can detect Alzheimer’s risk
April 25, 2019 - Computer program mimics natural speech using brain signals from epilepsy patients
April 25, 2019 - Physicians turning to antibiotic alternatives for long-term acne treatment
April 25, 2019 - Preschool Is Prime Time to Teach Healthy Lifestyle Habits
April 25, 2019 - Study finds insidious and persistent discrimination among physician mothers
April 25, 2019 - Newly identified skin-gut communication helps illuminate link between food allergy and eczema
April 25, 2019 - Thiazide use linked with reduced risk of low energy fractures in people with Alzheimer’s
April 25, 2019 - Some women are biologically more resilient than others to PTSD
April 25, 2019 - The Current issue of “The view from here” is concerned with Partnerships and Alliances
April 25, 2019 - Imaging method reveals long-lived patterns in cells of the eye
April 25, 2019 - Podcast: KHN’s ‘What The Health?’ The Abortion Wars Rage On
April 25, 2019 - Prolonged exposure therapy is more effective in treating veterans with PTSD, alcohol use disorder
April 24, 2019 - Our artificial cornea breakthrough could lead to self-assembling organs
April 24, 2019 - A Stanford black, female, gay surgery resident speaks out
April 24, 2019 - Donna Lynne on Extreme Sports, Lessons From the '60s, and Taking CUIMC to the Next Level
April 24, 2019 - Pain Clinics’ Doctors Needlessly Tested Hundreds Of Urine Samples, Court Records Show
April 24, 2019 - Researchers uncover potential clue to halt destruction of nerve cells in people with ALS
April 24, 2019 - Study uncovers reasons for poor mental health in bisexual people
April 24, 2019 - Screenings, interventions, and referrals can help adolescents overcome substance abuse
April 24, 2019 - Febrile seizures following vaccination are self-resolving and not dangerous
April 24, 2019 - Flow-UV inline UV-Visible spectrometer monitors dispersion in real time
April 24, 2019 - Rates of Marijuana Use in Cancer Patients on the Rise in U.S.
CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

image_pdfDownload PDFimage_print

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food.

The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+ NSCLC who had progressed on crizotinib. Patients were randomized to receive one of two regimens of ALUNBRIG: 90 mg of ALUNBRIG once daily (n=112) or 180 mg once daily with seven-day lead-in at 90 mg once daily (n=110).

“ALK+ NSCLC is a serious and life-threatening disease that affects approximately 40,000 people worldwide every year, and many patients will progress on or stop responding to first-line treatment,” said Stefania Vallone, President, Lung Cancer Europe. “For European people with ALK+ NSCLC, there remains a significant unmet need for new and effective treatment options.”

“While ALK inhibitors have demonstrated tremendous growth in this treatment space over the past decade, having an additional targeted therapy option available for the treatment of ALK+ NSCLC has been eagerly anticipated,” said Enriqueta Felip, M.D., PhD, Head of the Thoracic Oncology Unit, Oncology Department at Vall d’Hebron University Hospital in Barcelona. “With a median progression-free survival of 16.7 months and overall survival of 34.1 months, ALUNBRIG has shown impressive results, representing new progress for ALK+ NSCLC treatment in this setting.”

“The ALTA trial has established ALUNBRIG as a potential second-line treatment option for ALK+ NSCLC, by demonstrating significant efficacy with a manageable safety profile,” said Jesús Gómez-Navarro, M.D., Vice President, Head of Oncology Clinical Research and Development, Takeda. “With 16.7 months median progression-free survival, the longest of any ALK inhibitor to be reported in this setting, ALUNBRIG offers great potential for patients who progressed on crizotinib. Today’s positive opinion brings us closer toward the ultimate goal of advancing the treatment paradigm for the considerable number of crizotinib-treated ALK+ NSCLC patients living in Europe. We look forward to the European Commission’s review of the CHMP positive opinion and introducing ALUNBRIG to patients and healthcare professionals in the European Union if approved.”

As part of this submission, the CHMP also reviewed data from the first interim analysis of the Phase 3 ALTA-1L trial, which met its primary endpoint, as supportive evidence. In ALTA-1L, treatment with ALUNBRIG resulted in a statistically and clinically significant improvement in PFS versus crizotinib as assessed by a blinded independent review committee. The safety profile associated with ALUNBRIG was generally consistent with prior studies and approved U.S. and Canadian labeling.

The CHMP positive opinion for ALUNBRIG will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 member states of the European Union, as well as Norway, Liechtenstein and Iceland.

Source:

https://www.takeda.com/newsroom/newsreleases/2018/takeda-receives-positive-chmp-opinion-recommending-alunbrig-brigatinib-for-the-treatment-of-alk-non-small-cell-lung-cancer-in-patients-previously-treated-with-crizotinib/

Tagged with:

About author

Related Articles